Thursday, July 17, 2025
Welcoming Remarks
Harold Burstein
8:00-8:15 am
Session I: Radiation Oncology
8:15-9:50 am
50 Years of Radiation Therapy
Abram Recht
8:15-8:35 am
Standard Radiation Therapy: The Long and the Short
Julia Wong
8:35-8:55 am
The Future of Breast Radiation Therapy
Atif Khan
8:55-9:15 am
Radiopharmaceuticals
Heather Jacene
9:15-9:35 am
Q&A
Abram Recht; Atif Khan; Julia Wong; Heather Jacene
9:35-9:50 am
Session II: Pathology
9:50-10:45 am
Lobular Breast Cancer
Stuart Schnitt
9:50-10:10 am
ctDNA: The Evolving Role for Molecular Diagnostics
Stefania Morganti
10:10-10:30 am
Q&A
Stuart Schnitt; Stefania Morganti
10:30-10:45 am
Break
10:45-11:00 am
Special Lecture
11:00-11:40 am
What's New In Supportive Care: The Management of Gastrointenstinal Side Effects
Sydney Smith; Julie Bosworth
11:00-11:20 am
Essentials of Germline Genetics
Judy Garber
11:20-11:40 am
Q&A
Julie Bosworth; Sydney Smith; Judy Garber
11:40-11:50 am
Schwartz Rounds: A Complex Case
Ann Partridge
11:50 am-12:20 pm
Schwartz Rounds: Q&A
Ann Partridge
12:20-12:30 pm
Break
12:30-12:40 pm
Tumor Board: Early Breast Cancer
Harold Burstein; Faina Nakhlis; Julia Wong; Brittany Bychkovsky; Adrienne Waks; Filipa Lynce; Elizabeth Mittendorf
12:40-1:40 pm
Break
1:40-1:50 pm
Session III: HER2 Positive Breast Cancer
1:50-3:05 pm
New Approaches in Early Stage HER2 Positive Breast Cancer
Adrienne Waks
1:50-2:10 pm
The Progress Continues: Late Stage HER2 Positive Breast Cancer
Sarah Sammons
2:10-2:30 pm
Can We Cure Metastatic Breast Cancer
Nancy Lin
2:30-2:50 pm
Q&A
Sara Tolaney; Sarah Sammons; Nancy Lin; Adrienne Waks
2:50-3:05 pm
Break
3:05-3:20 pm
Special Lecture
3:20-4:35 pm
Racial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype
Erica Warner
3:20-3:45 pm
Inflammatory Breast Cancer
Filipa Lynce
3:45-4:10 pm
Early Drug Discovery in Breast Cancer
Antonio Giordano
4:10-4:35 pm
Lifestyle/Diet/Exercise in Breast Cancer Patients
Jennifer Ligibel
4:35-5:00 pm
Reception
5:00-6:00 pm
Friday, July 18, 2025
Session IV: Surgery
8:00-9:35 am
Oncoplastic Reconstruction: Common Indications and Outcomes
Indranil Sinha
8:00-8:20 am
The Axilla After Neoadjuvant Therapy: How Much is Too Much?
Elizabeth Mittendorf
8:20-8:40 am
Implications of the SOUND Trial
Olga Kantor
8:40-9:00 am
Cryoblation Instead of Surgery
Francys Verdial
9:00-9:20 am
Q&A
Barbara Smith; Indranil Sinha; Olga Kantor; Francys Verdial; Elizabeth Mittendorf
9:20-9:35 am
Schlager Lecture: Immunotherapy in Early Breast Cancer: Today and Tomorrow
Marleen Kok
9:35-10:20 am
Break
10:20-10:35 am
Session V: Triple Negative Breast Cancer
10:35 am-12:10 pm
Small TNBCs: How Small Is Small Enough?
Steven Isakoff
10:35-10:55 am
Antibody Drug Conjugates in TNBC and Refractory ER Positive Metastatic Breast Cancer
Ana Garrido-Castro
10:55-11:15 am
Immunotherapy in TNBC
Guilherme Nader Marta
11:15-11:35 am
Managing Endocrine Side Effects of Immunotherapy
Elad Sharon
11:35-11:55 am
Q&A
Steven Isakoff; Ana Garrido-Castro; Guilherme Nader Marta; Elad Sharon
11:55 am-12:10 pm
Break
12:10-12:20 pm
Tumor Board: Advanced Breast Cancer
Rachel Freedman; Barbara Smith; Sarah Sammons; Erica Mayer; Laura Spring; Leticia Varella; Guilherme Nader Marta; Daniel Abravanel
12:20-1:30 pm
Break
1:30-1:40 pm
Session VI: ER Positive Breast Cancer
1:40-3:15 pm
New Approaches in Early ER Positive Breast Cancer
Erica Mayer
1:40-2:00 pm
PI3K Inhibitors in Metastatic Breast Cancer: Choosing the Right Target
Dejan Juric
2:00-2:20 pm
Advanced ER Positive Breast Cancer: A Surfeit of Choices
Seth Wander
2:20-2:40 pm
Emerging Antibody Drug Conjugates in ER Positive Breast Cancer
Paolo Tarantino
2:40-3:00 pm
Q&A
Erica Mayer; Seth Wander; Paolo Tarantino; Dejan Juric
3:00-3:15 pm
Break
3:15-3:30 pm
CDK4/6: Which One? For Whom? - Debate
Shana Berwick; Laura Spring
3:30-4:25 pm
ASCO Highlights
Harold Burstein
4:25-4:45 pm
Closing Remarks
Harold Burstein
4:45-4:50 pm